{"product_id":"iconplc-marketing-mix","title":"ICON (Ireland) Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eICON (Ireland) leverages specialized CRO services, premium pricing for expert clinical capabilities, global site networks for efficient trial delivery, and targeted B2B promotion to biopharma clients—driving strong positioning in clinical research.\u003c\/p\u003e\n\u003cp\u003eGo beyond this snapshot: purchase the full 4Ps Marketing Mix Analysis for ICON (Ireland) to get editable, presentation-ready insights on product strategy, pricing architecture, distribution channels, and promotional tactics—ready for reports, benchmarking, or strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFull-Service Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON (Ireland) offers full-service clinical development across Phases I–IV, handling study design, patient recruitment, and regulatory consulting to meet global standards; in 2024 ICON reported clinical services revenue of $3.1bn and managed \u0026gt;1,200 trials worldwide, reducing average development timelines by ~15% versus industry norms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized Trial Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON Ireland’s Decentralized Trial Solutions combine remote monitoring, wearable-device integration, and home health visits to boost retention and diversity; ICON reported a 20% faster enrollment and 15% higher retention in hybrid trials in 2024 versus site-only arms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON’s Specialized Laboratory Services run a global network of 35 central labs and 50+ bioanalytical sites that processed ~1.2 million assays in 2024, delivering high-quality genomic, immunology, and infectious-disease data to support personalized-medicine trials. These labs feed validated biomarker and sequencing results into ICON’s CTMS (clinical trial management system), giving sponsors a unified dashboard to track endpoints, reduce data latency by ~30%, and cut site queries. In 2024 lab services contributed roughly 18% of ICON’s revenue, underpinning integrated trial analytics and faster go\/no-go decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device and Diagnostic Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eICON Ireland provides medical device and diagnostic support, advising manufacturers on regulatory strategy and post-market surveillance to meet evolving EU Medical Device Regulation (MDR) and US FDA rules.\u003c\/p\u003e\n\u003cp\u003eThe firm’s teams helped reduce time-to-market by ~20% in 2024 for clients and managed post-market safety programs covering over 150 devices, supporting CE marking and 510(k)\/PMA submissions.\u003c\/p\u003e\n\u003cp\u003eICON’s services combine clinical ops, quality systems, and real-world evidence to accelerate launches while keeping compliance across 70+ markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory strategy: MDR, IVDR, FDA pathways\u003c\/li\u003e\n\u003cli\u003ePost-market: surveillance for 150+ devices (2024)\u003c\/li\u003e\n\u003cli\u003eTime-to-market: ~20% improvement (2024)\u003c\/li\u003e\n\u003cli\u003eGlobal reach: support across 70+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Data Analytics and AI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eICON uses advanced analytics and AI to optimize trial design and predict enrollment, reducing average site start-up time by ~22% and improving enrollment accuracy by ~18% based on 2024 internal benchmarks.\u003c\/p\u003e\n\u003cp\u003eBy combining real-world evidence and 10+ years of historical trial data, ICON delivers actionable insights that shorten development timelines and can raise the probability of regulatory success by an estimated 6–9%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-world data: 10+ years, \u0026gt;5M patient records\u003c\/li\u003e\n\u003cli\u003eEnrollment accuracy: +18% (2024)\u003c\/li\u003e\n\u003cli\u003eSite start-up time: −22% (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated regulatory success lift: 6–9%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICON Ireland: $3.1B clinical revenue, labs 18% — faster enrollment, higher retention, proven wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON Ireland delivers end-to-end clinical development, decentralized trials, and lab\/device support, driving 2024 revenues: clinical services $3.1bn, labs 18% of revenue; operational wins: \u0026gt;1,200 trials, ~1.2M assays, 20% faster enrollment, 15% higher retention, −22% site start-up, +18% enrollment accuracy, estimated +6–9% regulatory success.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical rev\u003c\/td\u003e\n\u003ctd\u003e$3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials managed\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\u003c\/td\u003e\n\u003ctd\u003e~1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab rev %\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment speed\u003c\/td\u003e\n\u003ctd\u003e+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite start-up\u003c\/td\u003e\n\u003ctd\u003e−22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnroll accuracy\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into ICON (Ireland)’s Product, Price, Place, and Promotion strategies; ideal for managers and consultants needing a clear breakdown of ICON’s marketing positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses ICON Ireland’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product, price, place, and promotion strategies for faster decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Office Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON operates physical offices in over 50 countries, enabling navigation of local regulations and cultural nuances; as of 2025 they support trials across 120+ global sites per program on average. Their footprint lets them run large multi-regional trials for top pharma clients—ICON reported €4.8bn revenue in 2024 with 60% from large-molecule drug development. Local teams manage site relationships and standardize data integrity across jurisdictions, cutting start-up times by ~18% in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccellacare Site Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary Accellacare site network gives ICON direct access to 1,200+ investigators and an active patient pool across 25+ therapeutic areas, cutting average site start-up time by ~30% and improving recruitment predictability—ICON reported 2024 per-protocol enrollment rates up to 20% faster than industry benchmarks. Controlling the site environment boosts data quality, lowers query rates, and reduces trial execution costs through standardised processes and tighter oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Dublin Headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON’s Dublin headquarters anchors global strategy and operations from Ireland, giving direct access to the EU market of 448 million people and a life sciences talent pool where Dublin metro added 12,000 pharma\/biotech jobs 2019–2024; the site supports regulatory engagement with EMA and national agencies—crucial for drug approvals—and helped ICON report €3.9bn revenue in FY2024, reflecting strong Europe-driven growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient Recruitment Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICON uses digital patient recruitment portals to reach global participants outside physical sites, boosting outreach and speeding enrollment; in 2024 ICON reported digital recruitment cut screen-to-randomization time by ~20% in oncology trials.\u003c\/p\u003e\n\u003cp\u003eThese web interfaces simplify screening and consent, improving inclusivity—remote enrollment raised underrepresented group participation by an estimated 12% in 2023 pilot programs.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eGlobal reach—remote access to trials\u003c\/li\u003e\n\u003cli\u003e20% faster screen-to-randomization (2024)\u003c\/li\u003e\n\u003cli\u003e12% higher underrepresented enrollment (2023)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Logistics and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICON Ireland runs a global logistics network for investigational medicinal products, with over 120 specialized cold-chain partners and temperature-controlled storage across 30+ countries as of 2025, ensuring biologics remain within required ranges during transit.\u003c\/p\u003e\n\u003cp\u003eThe company uses validated specialized transport and real‑time monitoring, cutting temperature excursion incidents to under 0.5% and supporting continuity for 1,200+ active trials in remote sites in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ cold-chain partners\u003c\/li\u003e\n\u003cli\u003e30+ countries with temp-controlled storage\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.5% temperature excursions\u003c\/li\u003e\n\u003cli\u003eSupports 1,200+ active trials (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICON Ireland: Global trials speed—18% faster start-up, 20% quicker recruitment, robust cold chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON Ireland’s place combines 50+ country offices, 120+ global sites per program (2025), and Accellacare’s 1,200+ investigators to speed start-up ~18% and recruitment ~20% (2024); Dublin HQ links EMA\/regulatory access and a 12,000-strong life sciences hiring surge (2019–2024). Cold-chain network: 120+ partners, 30+ countries, \u0026lt;0.5% excursions, supporting 1,200+ active trials (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffices\u003c\/td\u003e\n\u003ctd\u003e50+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\/program\u003c\/td\u003e\n\u003ctd\u003e120+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccellacare investigators\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStart-up reduction\u003c\/td\u003e\n\u003ctd\u003e~18% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecruitment speed\u003c\/td\u003e\n\u003ctd\u003e20% faster (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain partners\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemperature storage\u003c\/td\u003e\n\u003ctd\u003e30+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemp excursions\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eICON (Ireland) 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual ICON (Ireland) 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750078886265,"sku":"iconplc-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/iconplc-marketing-mix.png?v=1772221818","url":"https:\/\/growthsharematrix.com\/products\/iconplc-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}